The results feed into an effort to identify to monoclonal antibody combinations that would prevent and possibly treat HIV ...

Higher intakes of diet beverages and/or saccharin are associated with an increased risk of developing diabetes over the long ...

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

IntegriMedical has introduced a needle-free injection system (N-FIS) that eliminates the need for any prick or piercing, ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

The new version of Sarclisa stems from a collaboration with Enable Injections, backed financially to the tune of €300 million ...

This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. "These long-term results build ...

The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult ...

The analyst informs investors that the business recently released positive topline data from the phase 3 ORIGIN study of ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN) ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing ...

Visceral fat, which accumulates around vital organs, is metabolically active and can have harmful health effects.